to-BBB Announces Successful €10 Million Financing

Round C financing of €10 million with new and existing investors

02-Jul-2014 - to-BBB announced the successful finalization of a round C financing of €10 million with new and existing investors. The company also announced the appointment of Dr. Pericles (Perry) Calias as Senior Vice President Translational Medicine and the appointment of Leonard Kruimer as interim CEO to ...

to-BBB Further Strengthens Supervisory Board with Dr. Peter Høngaard Andersen

12-Sep-2013 - to-BBB announced the addition of Dr. Peter Høngaard Andersento its SupervisoryBoard. Dr. Andersen brings many years of pharma drug development experience tothe Board. Hisexperience and strategic guidance will be instrumental tofurther build to-BBB as a leading company in brain ...

ALS TDI and to-BBB collaborate on potential treatments for Motor Neuron Disease

14-Jan-2013 - TheALS Therapy Development Institute(ALS TDI)announcedthat it has entered into a new collaboration withto-BBBto investigate potential treatments for ALS (aka Motor Neuron or LouGehrig’sdisease). The blood-brain barrier (BBB) fortifies thewalls of blood vessels to prevent the entry of ...

to-BBB receives Frost & Sullivan Technology Innovation Award

03-Dec-2012 - to-BBB has been awarded the 2012 European CNS Targeted Drug Delivery Technology Innovation Award by Frost & Sullivan that is based on extensive research carried out by a team of healthcare analysts.CNS disorders are a major cause of mortality and debilitation. With increasing prevalence of ...

to-BBB awarded EUR 1.25 million European FP7 funding to develop treatments for inherited retinal diseases

05-Sep-2012 - to-BBB has been awarded funding of EUR 1.25 million by the European Commission’s 7th Framework Programme as part of a EUR 5 million consortium project for the preclinical development of novel treatments for inherited retinal degenerative diseases. The consortium additionally consists of ...

to-BBB receives Michael J. Fox Foundation funding for Parkinson’s disease research

24-Apr-2012 - to-BBB has been awarded funding by The Michael J. Fox Foundation (MJFF) to conduct preclinical research targeting neuroinflammation in Parkinson’s disease (PD) with its second product in development, 2B3-201. This is to-BBB’s first grant from MJFF.“We strongly believe that we can create better ...

to-BBB receives International Innovation grant to support partnership with top-5 pharma company

22-Dec-2011 - to-BBB has been awarded a grant of over €600,000 through the “Internationaal Innoveren” program of the Dutch government agency Agentschap NL to support a brain drug delivery partnership with a top-5 pharma company. This work will facilitate future license deals with to-BBB’s brain cancer product ...

NeuroVive and to-BBB awarded Eurostars grant for development of stroke therapy

04-Oct-2011 - NeuroVive Pharmaceutical AB and to-BBB have been awarded a grant of €1 million through the Eureka Eurostars program for the joint development of therapies for stroke and other acute neurological conditions.The Eurostars program has awarded NeuroVive Pharmaceutical and to-BBB technologies, a grant ...

to-BBB starts clinical trial in patients with brain metastases

29-Jun-2011 - to-BBB announced that it has received approval to start treating patients with brain metastases with its lead product 2B3-101 in a Phase I/II clinical trial.Based on its proprietary G-Technology®, to-BBB is developing its lead compound 2B3-101, brain-targeted doxorubicin liposomes. These ...

to-BBB obtains government loan of €1.2 million for clinical trial in brain cancer

04-Apr-2011 - to-BBB is getting ready to point its brain-targeting platform to patients with brain cancer. The Dutch Ministry of Economic Affairs, Agriculture and Innovation (Agentschap NL) supports to-BBB in this challenge by granting an “Innovation Credit”, covering 35% of the costs needed for clinical ...